Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.68 |
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.60 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | MITF | O75030 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7251623 | 0.92 | SMN1; SMN2 (0.72) | SMN1; SMN2HPGDPTPN1RAB9ANPC1 | |
| SCHEMBL282531 | 0.87 | SMN1; SMN2 (0.71) | SMN1; SMN2HPGDRAB9ANPC1TAAR1 | |
| SCHEMBL8884482 | 0.85 | SMN1; SMN2 (0.69) | SMN1; SMN2HPGDRAB9ANPC1ALDH1A1 | |
| SCHEMBL9609808 | 0.85 | SMN1; SMN2 (0.82) | SMN1; SMN2HPGDRAB9ANPC1ALDH1A1 | |
| SCHEMBL9125125 | 0.84 | SMN1; SMN2 (0.63) | SMN1; SMN2HPGDRAB9ANPC1ALDH1A1 | |
| SCHEMBL9479507 | 0.84 | HPGD (0.68) | SMN1; SMN2HPGDRAB9ANPC1ALDH1A1 | |
| SCHEMBL2094875 | 0.83 | MGLL (0.68) | MEN1KMT2A | |
| SCHEMBL9127154 | 0.83 | HSD17B1 (0.55) | SMN1; SMN2HPGDRAB9ANPC1LMNA | |
| SCHEMBL13680466 | 0.83 | FAAH (0.56) | SMN1; SMN2HPGDALDH1A1KMT2A | |
| SCHEMBL2092940 | 0.82 | PTPN1 (0.58) | SMN1; SMN2HPGDPTPN1PTPN11RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507453-B2 | Anti-penicillin resistant pneumococci agent and novel 16-membered macrolide derivative | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2013-08-13 | — | — | US | disclosed |
| US-8507453-B2 | Anti-penicillin resistant pneumococci agent and novel 16-membered macrolide derivative | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2013-08-13 | — | — | US | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20120015896-A1 | Anti-Penicillin Resistant Pneumococci Agent and Novel 16-Membered Macrolide Derivative | MICROBIAL CHEMISTRY RESEARCH FOUNDATION | 2012-01-19 | — | — | US | disclosed |
| US-20120015896-A1 | Anti-Penicillin Resistant Pneumococci Agent and Novel 16-Membered Macrolide Derivative | MICROBIAL CHEMISTRY RESEARCH FOUNDATION | 2012-01-19 | — | — | US | disclosed |
| US-8053418-B2 | Anti-penicillin resistant pneumococci agent and novel 16-membered macrolide derivative | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2011-11-08 | — | — | US | disclosed |
| US-8053418-B2 | Anti-penicillin resistant pneumococci agent and novel 16-membered macrolide derivative | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2011-11-08 | — | — | US | disclosed |
| US-20080300388-A1 | Anti-Penicillin Resistant Pneumococci Agent and Novel 16-Membered Macrolide Derivative | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2008-12-04 | — | — | US | disclosed |
| US-20080300388-A1 | Anti-Penicillin Resistant Pneumococci Agent and Novel 16-Membered Macrolide Derivative | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2008-12-04 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| US-4069240-A | GROUP 8 METAL CATALYST | UNIROYAL, INC. (US) | 1978-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015896-A1 | Anti-Penicillin Resistant Pneumococci Agent and Novel 16-Membered Macrolide Derivative | PWWP2B, BRWD1, BAZ1A | SMN1; SMN2 3529/4885HPGD 1581/4885PTPN1 2270/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | SMN1; SMN2 3787/4885HPGD 1951/4885PTPN1 1076/4885 |
| US-20080300388-A1 | Anti-Penicillin Resistant Pneumococci Agent and Novel 16-Membered Macrolide Derivative | PWWP2B, BRWD1, BAZ1A | SMN1; SMN2 3529/4885HPGD 1581/4885PTPN1 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.